Investigation of an Updated Bone-anchored Sound Processor

BC109 - Investigation of an Updated Bone-anchored Sound Processor

The study is a prospective, single-center, comparative, cross-over study with within-subject control design. In the investigation an updated sound processor will be tested at compared to the CE marked Ponto 3 SuperPower sound processor (available on the market since December 2016) in order to establish marketing claim(s) on the updated sound processor.

The performance of the two sound processors will be evaluated via speech and hearing tests, and patient reported outcomes.

Study Overview

• Status: Completed
• Conditions: Nervous System Diseases; Neurologic Manifestations; Otorhinolaryngologic Diseases; Ear Diseases; Sensation Disorders; Hearing Loss; Hearing Disorders; Deafness; Hearing Loss, Conductive; Hearing Loss, Mixed
• Intervention / Treatment: Device: Device A; Device: Device B

Detailed Description

The investigation is a premarket investigation with the purpose of gathering knowledge on the performance of an updated sound processor compared to the CE marked Ponto 3 SuperPower sound processor to establish marketing claim(s) on the updated sound processor.

The recruitment for this clinical investigation will be performed among subjects who have already received a Ponto 3 SuperPower sound processor as a minimum three month prior to the study. 12-15 adult Ponto 3 SuperPower users with a conductive, mixed hearing loss or single-sided deafness will be included.

The study is a prospective, single-center, comparative, cross-over study with within-subject control design. The study includes four laboratory visits and three field trial periods. After the first trial period, which is included to ensure a homogenous baseline, the study is designed as a two-period, two-sequence crossover trial to compare the two sound processors (Device A & Device B). Each participant is randomized into one of two sequences: (1) Device A then B, or (2) Device B then A, such that (about) half of the participants are assigned to one sequence and the other half to the second sequence.

This study is designed to combine audiological assessments (hearing and speech tests) in the laboratory and subjective self-reported outcomes collected during and after field trial periods with the investigational device and the comparator device (Ponto 3 SuperPower). The primary outcome of this study is to demonstrate that Open Sound Navigator in the updated sound processor provides subjects with improved speech recognition in noise.

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Smørum
    • Copenhagen, Smørum, Denmark, 2765
      • Oticon Medical c/o Oticon A/S

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Signed Informed Consent Form
2. Adult subjects (18 years or older)
3. Subjects using a Ponto 3 SuperPower on Oticon Medical compatible abutment
4. Experienced BAHS users with a minimum experience of 3 months.

5. Subjects with:

   1. conductive or mixed hearing loss with pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear better than or equal to 65 dB HL as measured in situ with Ponto 3 SuperPower at Visit 1.
   2. OR subjects who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., SSD). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz) as reported in the patient's Noah file.
   3. OR subjects who are indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS (as per investigator discretion).
6. Fluent in Danish

Exclusion Criteria:

Subjects meeting any of the following criteria will not be permitted to participate in the investigation:

1. Known abnormally progressive BC hearing loss as judged by the investigator
2. Subjects with known mixed losses where the sensorineural part of the hearing loss is of retro-cochlear or central origin
3. Participation in another clinical investigation which might cause interference with study participation.
4. Subjects who do not have the ability or are un-willing to follow investigational procedures/requirements, e.g. to complete questionnaires, according to investigator's discretion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: AAB; Starts with Device A in first and second trial period and change to Device B in third trial period.	Device: Device A; Participant wear Device A and evaluate the performance of the device.; Device: Device B; Participant wear Device B and evaluate the performance of the device.
Active Comparator: ABA; Starts with Device A in first trial period, wears Device B in second trial period and change to Device A in third trial period.	Device: Device A; Participant wear Device A and evaluate the performance of the device.; Device: Device B; Participant wear Device B and evaluate the performance of the device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To demonstrate that OSN in Device A provides subjects with improved speech recognition in noise.	Difference in signal-to-noise ratio at 70% correct (referred to as SRT70) between OSN OFF and OSN ON after field trial with Device A (incl. automatics).	4 weeks or 6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the preference of BAHS sound processor.	Percentage (%) of subjects who prefer Device A over Device B in noisy sound environments.	6 weeks
To assess the improvement of hearing with Device A.	Functional gain with Device A, i.e. the difference in dB between unaided and aided sound field thresholds, for frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz.; Functional gain with Device A, see definition above, calculated on average for frequencies 500, 1000, 2000 and 4000 Hz (PTA4).	Baseline
To assess the degree to which Device A compensates for the BC hearing loss for the group CHL/MHL	Effective gain defined as the difference in dB between aided sound field thresholds with Device A, and BC in-situ thresholds on the aided ear(s). The effective gain is calculated for frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz.; Effective gain with Device A, see definition above, calculated in average for frequencies 500, 1000, 2000 and 4000 Hz (PTA4).	Baseline
To assess the improvement in speech recognition with Device A in quiet.	Difference in speech recognition score in percent between unaided and aided, assessed in quiet on the aided ear(s).	2 weeks
To assess performance in speech recognition in noise with Device A and Device B in Omni settings.	Difference in SRT70 between Device A and Device B in Omni settings as measured at Visit 1.	Baseline
To assess the improvement in speech recognition in noise with Device B in full directional settings as compared to omnidirectional.	Difference in signal-to-noise ratio at 70% correct (referred to as SRT70) between Omni and Full Dir after field trial with Device B.	4 weeks or 6 weeks
To compare the improvement in speech recognition in noise with OSN ON in Device A (re Omni) with the improvement of full directionality in Device B (re Omni).	Comparison of the difference in SRT70 between OSN OFF vs. OSN ON in Device A and Omni vs. Full Dir in Device B.	4 weeks or 6 weeks
To assess self-reported performance with Device A and Device B.	Average SSQ12 scores with Device A for each question, sub-scales and in total.; Average SSQ12 scores with Device B for each question, sub-scales and in total.; Difference in SSQ12 scores between Device A and Device B for each question, sub-scales and in total.	4 weeks or 6 weeks
To assess self-reported ratings of sound quality, speech intelligibility, and overall performance with Device A and Device B.	Average ratings with Device A for each question of the "SPSK sound quality" questionnaire completed during the 1. field trial with Device A as obtained via phone interview; Average ratings with Device A for each question of the "SPSK sound quality" questionnaire completed during the 2. or 3. field trial with Device A; Average ratings with Device B for each question of the "SPSK sound quality" questionnaire completed during the 2. or 3. field trial with Device B; Difference in ratings between Device A and Device B for each question of the "SPSK sound quality" questionnaire; Average ratings with Device A for each question of the "SPSK situations" questionnaire completed during the 2. or 3. field trial with Device A; Average ratings with Device B for each question of the "SPSK situations" questionnaire completed during the 2. or 3. field trial with Device B; Difference in ratings between Device A and Device B for each question of the "SPSK situations" questionnaire	1 week, 4 weeks and 6 weeks
To assess the difference in BC thresholds as measured in-situ with Device A and via conventional BC audiometry.	Difference in dB between BC in situ thresholds and BC thresholds measured with conventional BC audiometry.	Baseline and 2 weeks
To assess the difference in BC thresholds as measured in-situ with Device A and Device B.	Difference in dB between BC in situ thresholds measured with Device A and Device B.	Baseline
To confirm the safety profile of the Device A in terms of the occurrence of adverse events and serious adverse events.	Tabulated adverse events and serious adverse event related to the Device A reported throughout the study.	1 week, 2 weeks, 4 weeks and 6 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the improvement in speech recognition in noise with Device A with OSN ON vs. OSN OFF as a function of hearing loss.	Correlation of the difference between OSN OFF and OSN ON after field trial with Device A (incl. automatics) and PTA4 BC in situ for subjects with SSD and subjects with conductive/mixed hearing loss.	Baseline and week 4 or week 6
To list comments and reactions from the subjects with Device A and Device B.	Immediate reactions collected with each sound processor before field trial.	Baseline, 2 weeks and 4 weeks
To list comments and reactions from the subjects with Device A and Device B.	Comments on any difference between phone interview and subject's feedback collected at V2 after first field trial with Device A (without automatics).	2 weeks
To assess usage of device for each field trial period.	Average hours of usage of each sound processor for each field trial.	2 weeks, 4 weeks and 6 weeks
To assess usage of device and batteries for each field trial period.	Frequency of battery replacement for each sound processor for each field trial.	2 weeks, 4 weeks and 6 weeks

Collaborators and Investigators

• Sponsor: Oticon Medical
• Investigators: Principal Investigator: Mona El Hichou, MSc, Oticon Medical c/o Oticon A/S

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2021
• Primary Completion (Actual): December 13, 2021
• Study Completion (Actual): December 13, 2021

Study Registration Dates

• First Submitted: September 27, 2021
• First Submitted That Met QC Criteria: October 7, 2021
• First Posted (Actual): October 21, 2021

Study Record Updates

• Last Update Posted (Actual): April 20, 2022
• Last Update Submitted That Met QC Criteria: April 19, 2022
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: BAHS; Ponto
• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Nervous System Diseases; Hearing Loss; Deafness; Hearing Disorders; Sensation Disorders; Neurologic Manifestations; Hearing Loss, Conductive; Ear Diseases; Otorhinolaryngologic Diseases; Hearing Loss, Mixed Conductive-Sensorineural
• Other Study ID Numbers: BC109

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No